Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
Open accessPublished version of a preprint
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
5-Fluorouracil (5-FU) continues to be widely used for treatment of gastrointestinal cancers. Because many tumors show primary or acquired resistance, it is important to understand the molecular basis underlying the mechanism of resistance to 5-FU. In addition to its effect on thymidylate synthase inhibition and DNA synthesis, 5-FU may also influence RNA metabolism. Our previous studies revealed that colorectal cancer cells resistant to bolus 5-FU (HCT-8/4hFU) showed significantly decreased incorporation of the drug into RNA. Resistance to bolus 5-FU was associated with lower expression of UMP kinase (UMPK), an enzyme that plays an important role in the activation of 5-FU to 5-FUTP and its incorporation into RNA. Activities of other 5-FU–metabolizing enzymes (e.g., thymidine kinase, uridine phosphorylase, thymidine phosphorylase, and orotate phosphoribosyltransferase) remained unchanged between sensitive and resistant cell lines. Herein, we show that UMPK down-regulation in 5-FU–sensitive cells (HCT-8/P) induces resistance to bolus 5-FU treatment. Moreover, HCT-8/4hFU cells are even more cross-resistant to treatment with 5-fluorouridine, consistent with the current understanding of 5-fluorouridine as a RNA-directed drug. Importantly, colorectal cancer hepatic metastases isolated from patients clinically resistant to weekly bolus 5-FU/leucovorin treatment exhibited decreased mRNA expression of UMPK but not thymidylate synthase or dihydropyrimidine dehydrogenase compared with tumor samples of patients not previously exposed to 5-FU. Our findings provide new insights into the mechanisms of acquired resistance to 5-FU in colorectal cancer and implicate UMPK as an important mechanism of clinical resistance to pulse 5-FU treatment in some patients.[Mol Cancer Ther 2009;8(4):OF1–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been proven that the lower expression of these metabolic enzymes is associated with 5-FU resistance in CRC patients [6,7,8].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“A low expression of TP gene and high expression of DPD also have been correlated with resistance to 5-FU (27).”
BackgroundRed Cell Metabolism: A Manual of Biochemical Methods.
(1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-75-6-985_1 · Cited by 2,321
Red Cell Metabolism. A Manual of Biochemical Methods.
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-6-919_1 · Cited by 1,751
Clinical Pharmacology of 5-Fluorouracil
Diasio, R. B., & Harris, B. E. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916040-00002 · Cited by 969
Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience
Wei, A. C., Greig, P. D., Grant, D., Taylor, B., Langer, B., & Gallinger, S. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.05.039 · Cited by 374
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Sobrero, A. F., Aschele, C., & Bertino, J. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.368 · Cited by 336
Self-citationPhosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases
Van Rompay, A. R., Johansson, M., & Karlsson, A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00048-6 · Cited by 244
Pritchard, D. M., Watson, A. J. M., Potten, C. S., Jackman, A. L., & Hickman, J. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1795 · Cited by 198
Peters, G. J., van der Wilt, C. L., van Groeningen, C. J., Smid, K., Meijer, S., & Pinedo, H. M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2035 · Cited by 196
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Blondy, S., David, V., Verdier, M., Mathonnet, M., Perraud, A., & Christou, N. (2020) · Cancer Science · doi:10.1111/cas.14532 · Cited by 507
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
Metadata
- Authors
- Humeniuk, R., Menon, L. G., Mishra, P. J., Gorlick, R., Sowers, R., Rode, W., Pizzorno, G., Cheng, Y.-C., Kemeny, N., Bertino, J. R., & Banerjee, D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Banerjee, Debabrata
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-05-01
- Volume
- 8
- Issue
- 5
- Pages
- 1037-1044
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2143037829
- Cited by
- 50
- References
- 34
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 4 · 2012: 1
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Cancer Institute (CA63477)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- UMP kinase, 5-fluorouracil resistance, fluoropyrimidine resistance, 5-fluorouridine, RNA metabolism, thymidine kinase, uridine phosphorylase, thymidine phosphorylase, orotate phosphoribosyltransferase, thymidylate synthase, dihydropyrimidine dehydrogenase, colorectal cancer, liver metastasis, acquired drug resistance, HCT-8 cells
- MeSH terms
- Colonic Neoplasms, Humans, Liver Neoplasms, Nucleoside-Phosphate Kinase, Uridine, Down-Regulation, Drug Resistance, Neoplasm, RNA Interference, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0716
- The paper
- Humeniuk, R., Menon, L. G., Mishra, P. J., Gorlick, R., Sowers, R., Rode, W., Pizzorno, G., Cheng, Y.-C., Kemeny, N., Bertino, J. R., & Banerjee, D. (2009). Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0716
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.